研究分析在经饮食和运动不能有效控制血糖的2型糖尿病患者中比较新药A在1

The study analyzes whether the new drug A is better than placebo treatment at a dose of 12 mg/day for 16 weeks in patients with type 2 diabetes who cannot effectively control blood sugar through diet and exercise. At the same time, it is not inferior to alogliptin benzoate 25 mg/ Days of effectiveness research. Select 16 patients with type 2 diabetes in a hospital. These patients will be randomly assigned to the experimental drug group, positive control group or placebo group at a ratio of 2:1:1 and be treated according to the dosing regimen. Compare the treatments of the three groups of patients Effect and various test indicators. According to the guidelines for prevention and treatment of type 2 diabetes, glycosylated hemoglobin is the gold standard for evaluating blood sugar control, so it is used as the main indicator in this study. After treatment, the fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) levels of the test group and the control group decreased significantly (P<0.05), the placebo group fluctuated little, and the test group was lower than the control group (P<0.05) ), the difference was statistically significant (P<0.05). A new drug A is more effective than alogliptin benzoate in type 2 diabetes that cannot effectively control blood sugar through diet and exercise.

The study analyzed whether the new drug A was better than placebo treatment for 16 weeks at 12 mg/day dose in patients with type 2 diabetes who could not control blood sugar effectively through diet and exercise, and whether it was not inferior to the effectiveness of 25 mg/day of aletin benzoic acid. Select a hospital type II diabetes patients 16 cases, these patients will be randomly assigned to the experimental drug group, positive control group or placebo group in a 2:1 ratio and according to the treatment plan, compare the treatment effect of three groups of patients and various test indicators, which according to the prevention and treatment guidelines of type 2 diabetes, glycation hemoglobin is the gold standard for evaluating blood sugar control, so in this study as the main indicator. After treatment, there was a significant decrease in the verage of conceded blood sugar (FPG), glycoglobin (HbA1c) in the trial and control groups (P

Objective to compare the efficacy of new drug a in patients with type 2 diabetes mellitus whose blood glucose can not be effectively controlled by diet and exercise, and whether it is better than placebo treatment at the dose of 12 mg / day for 16 weeks, while it is not inferior to the efficacy of acigliptin benzoate 25 mg / day. 16 patients with type 2 diabetes mellitus in a hospital were randomly assigned to the experimental drug group, positive control group or placebo group in the ratio of 2:1:1, and were treated according to the administration scheme. The therapeutic effect and various test indexes of the three groups were compared. According to the prevention and treatment guidelines for type 2 diabetes mellitus, glycosylated hemoglobin is the gold standard for evaluating blood glucose control, so it is necessary to improve the quality of blood glucose control It is used as the main index in this study. After treatment, the levels of fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) in the experimental group and the control group were significantly decreased (P < 0.05), the fluctuation of the placebo group was not significant, and the experimental group was lower than the control group (P < 0.05), the difference was statistically significant (P < 0.05). A new drug a is more effective than agliptin benzoate in the treatment of type 2 diabetes mellitus whose blood glucose can not be effectively controlled by diet and exercise.<br>